LivaNova PLC $LIVN Shares Bought by Millennium Management LLC

Millennium Management LLC increased its position in LivaNova PLC (NASDAQ:LIVN) by 17.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,484,082 shares of the company’s stock after acquiring an additional 514,268 shares during the period. Millennium Management LLC owned approximately 0.06% of LivaNova worth $214,376,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. lifted its holdings in shares of LivaNova by 159.9% in the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after buying an additional 267 shares during the period. State of Wyoming acquired a new stake in shares of LivaNova in the second quarter valued at $31,000. Quarry LP acquired a new stake in shares of LivaNova in the third quarter valued at $36,000. EverSource Wealth Advisors LLC lifted its holdings in shares of LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares during the period. Finally, Covestor Ltd lifted its holdings in shares of LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

LIVN has been the subject of several research analyst reports. Stifel Nicolaus set a $80.00 price objective on LivaNova in a report on Wednesday, February 25th. Needham & Company LLC upped their price objective on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Piper Sandler restated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a report on Thursday, February 19th. Robert W. Baird cut their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Barclays upped their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and a consensus price target of $79.38.

LivaNova Stock Down 1.2%

Shares of LivaNova stock opened at $78.50 on Thursday. The stock’s fifty day moving average is $70.01 and its 200-day moving average is $66.14. The firm has a market capitalization of $4.31 billion, a PE ratio of 40.26 and a beta of 0.88. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 12-month low of $41.01 and a 12-month high of $80.96.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities analysts anticipate that LivaNova PLC will post 3.73 earnings per share for the current year.

Insider Activity

In other news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.35% of the stock is owned by company insiders.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.